KRAS and pancreatic neoplasm: Engineered exosomes as carriers for chemotherapeutic drugs and targeted RNA demonstrate potential for treating pancreatic cancer and its metastasis, including strategies targeting KRAS gene mutations, offering new directions for therapy.